Gedatolisib is a Potential First-in-Class PI3K/mTOR Inhibitor

Sara Hurvitz1, Fabrice Andre2, Massimo Cristofanilli3, Giuseppe Curigliano4, Antonio Giordano5, Hyo Han6

Breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1) is recruiting

A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)

VICTORIA-1 is a Phase 3, open-label, randomized, two-part clinical trial to evaluate the efficacy and safety of gedatolisib in combination with fulvestrant with and without palbociclib. Two cohorts based on PIK3CA mutation status will be enrolled in the trial. The primary completion date is estimated to occur in the second half of 2024

Study 2 (PIK3CA MT)

- Phase 1b trial (N=103) reported 62% ORR in 44 response evaluable patients across four expansion arms
- Median PFS not reached in 1L arm, and 12.9 months in 2L arm with Phase 3 dosing schedule
- 62% ORR in 94 response evaluable patients across four cohorts

Key Secondary Objectives
- Compare efficacy, as measured by PFS, of gedatolisib in combination with fulvestrant with and without palbociclib between Arm A and Arm B
- Compare efficacy, as measured by OS, of Arm C to Arm B and Arm A

Additional Objectives
- Evaluate tumour response in patients with HER2-positive disease
- Evaluate safety and tolerability in patients with HER2-negative disease
- Evaluate safety and tolerability of gedatolisib in combination with fulvestrant with and without palbociclib in patients with HER2-negative disease
- Evaluate changes in PI3KCA activity with gedatolisib in combination with fulvestrant with and without palbociclib

Study 1 (PIK3CA WT)

- Optimal Cut point from Arm C to Arm A or Arm B upon progressive disease

- Ongoing Study 1 from PIK3CA WT

- Investigate the safety, tolerability, and efficacy of gedatolisib in combination with fulvestrant with and without palbociclib in patients with HER2-negative disease

- Study 1 (PIK3CA WT)

- Study 2 (PIK3CA MT)

- Key Inclusion Criteria
- Multi-drug refractory hormone receptor positive advanced breast cancer
- Tumor progression on or after prior CDK4/6 inhibitor
- Adequate organ function
- Availability of eligible tumor tissue
- Women of childbearing potential are not taking an effective contraceptive method

- Key Exclusion Criteria
- Treatment with an immunomodulatory agent within 8 weeks of enrollment
- Treatment with a strong CYP3A4 inhibitor or inducer within 2 weeks of enrollment
- Treatment within 56 days of enrollment with a humanized monoclonal antibody or with a study drug
- Prior treatment with a denosumab-containing regimen

- Women of childbearing potential
- Liver or renal dysfunction
- Severe intercurrent illness

- Acknowledgements
- The authors would like to acknowledge the patients and their families/caregivers, investigators and their support staff for participating in the trial and Genentech, Inc. for sponsoring the study

Clinical Trial Registry Identifier: NCT03503818

This presentation is the intellectual property of the author/presenter. Contact genentechclinicaltrials@genentech.com for permission to reprint or distribute.

The primary endpoint is progression-free survival (PFS) in combination with fulvestrant and palbociclib (Arm A) compared to fulvestrant alone (Arm C) in patients whose disease progressed on or after PIK3CA-mutated CDK4/6 inhibitors.